AXIM Biotechnologies Appoints Dr Kelly K. Nichols, Dry Eye Specialist and Accomplished Optometrist, to Its Medical Advisory Board
Dr. Nichols strengthens his board of directors with 25 years of optometry and academic experience
SAN DIEGO, October 20, 2021 (GLOBE NEWSWIRE) – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech” or “the Company”), an international healthcare solutions company targeting oncological diseases, COVID -19 and Diagnosis of Dry Eye Disease (DED), today announced the appointment of Kelly K. Nichols, OD, MPH, Ph.D. to its Medical Advisory Board. Dr Nichols joins the other three new members of AXIM’s Advisory Board, including Drs Henry D. Perry, Laura Periman and President Joseph Tauber.
A founding member of the Ocular Surface Society of Optometry, Dr Nichols is currently Dean of the School of Optometry at the University of Alabama at Birmingham. She is a recognized expert in DED and ocular surface diseases and has been the subject of numerous publications. She received her second BS and PhD in Optometry (OD) from UC Berkeley, as well as an MPH in Biostatistics and a PhD. in Vision Science at Ohio State University.
“We are rapidly increasing the synergistic value of our medical advisory board by building it strategically,” said John W. Huemoeller II, Chairman and CEO of AXIM® Biotech. “Optometrists are the primary providers of eye health care in the United States and the front line of its eye and vision care. As a result, AXIM must communicate the benefits and accuracy of our DED diagnostic tests with optometrists nationwide as part of a collaboration to enable increased diagnosis of this often undiagnosed disease so that its millions of people can seek care. that they need.
“This will be essentially an educational process, and Dr. Nichols is a respected optometrist, professor and researcher with 20 years of academic experience in optometry who brings a keen insight into the culture of the optometrist community. American, ”continued Huemoeller. “She will help shape the marketing communications strategy for our two DED diagnostic tests in preparation for commercial launch from early 2022. I am delighted to welcome her to AXIM’s medical board.
Kelly K. Nichols, OD, MPH, Ph.D. Abstract Bio
Dr Nichols is currently Dean of the School of Optometry at the University of Alabama at Birmingham. She has served extensively on the Board of Directors and the Tear Film and Ocular Surface Society and each of the Steering Committees (DEWS, DEWS II, Contact Lens Discomfort and MGD workshops), and is a founding member of the Ocular Surface Society of Optometry . . She is currently President of the Association for Schools and Colleges of Optometry (ASCO) and Secretary of the National Alliance for Eye and Vision Research (NAEVR) / Alliance for Eye and Vision Research (AEVR).
Dr Nichols is a leading dry eye expert who has served on the editorial boards of the journals “Optometry and Vision Science” and “The Ocular Surface”. His research focuses on meibomian gland dysfunction, dry eye in menopause, the diagnosis and therapy of dry eye disease, and tear proteomics and lipidomics. She received her doctorate in optometry from the University of California at Berkeley, completed a residency in eye disease with Omni Eye Specialists of Colorado, and received her MPH in biostatistics and her doctorate. in Vision Science at Ohio State University.
Dry Eye Market
According to recent estimates of the prevalence of dry eye, over 26 million people in the United States and over 300 million worldwide suffer from dry eye disease. The prevalence is increasing in young and older adults, making it more urgent for clinicians to be better able to diagnose and treat DED. Up to two-thirds of patients with symptoms of dry eye have never been diagnosed by their doctor. Diagnosing DED is challenging due to the multifactorial nature of the disease, with symptoms similar to other eye surface conditions. It is well known that there is often a mismatch between signs and symptoms, highlighting the need for more sensitive and precise diagnostic tools.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the diagnostic landscape of SARS-CoV-2 (COVID-19), dry eye (DED) and oncological indications. AXIM’s COVID-19 Neutralizing Antibody Test is the first rapid diagnostic test to measure levels of functional neutralizing antibodies believed to prevent SARS-CoV-2 from entering host cells. In addition, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED. For more information, please visit www.AXIMBiotech.com.
Statements made by Axim Biotechnologies Inc. in this press release may be “forward-looking” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform. Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond Axim’s control. Biotechnologies, Inc. Actual results could differ materially from those projected due to lack of assurance that our diagnostic candidate will be successfully demonstrated to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for a use by the United States FDA or equivalent foreign regulatory agency, that the diagnostic candidate may be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, and The employer or individual use will make deals or buy from the Company, and even if the candidate diagnoses with the Company is successful, he cannot g generate only limited revenue and profit to the Company, including whether any of Axim’s diagnostic products will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and if and when, if at all, they will receive final approval from the US FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test using the antibodies neutralizers approved for use and various other factors detailed from time to time in Axim’s reports and documents with the SEC, including our annual report on Form 10-K filed April 15, 2021 and other reports that we file with the SEC, which are available at www. .sec.gov. Axim Biotechnologies, Inc., does not undertake to publicly update any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as otherwise required by law.
6191 Cornerstone Street, Ste. 114
San Diego, California 92121, USA